STOCKHOLM, August 10, 2016. Moberg Pharma AB (OMX:MOB) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application and that a No Objection Letter has been received from Health Canada to begin its Phase 3 trial for MOB-015 in the treatment of onychomycosis. This allows Moberg Pharma to start enrolling patients in the U.S. and Canada pending approval from the Institutional Review Board (IRB/independent ethics committee). The approvals concern a randomized, multicenter, vehicle-controlled Phase 3 study. The patients will be evaluated over 52 weeks and the primary endpoint will be the proportion of patients achieving complete cure of their target nail. The company expects to start enrollment in the third quarter of this year. About this information This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on August 10, 2016. About MOB-015 and Onychomycosis Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing rapidly after the recent introduction of new topical treatments in North America and Japan. Moberg Pharma expects the U.S. market alone to exceed $2 billion by 2020 and estimates the peak sales potential for MOB-015 to be in the range of $250-$500 million. MOB-015 is an internally developed topical formulation of terbinafine building on Moberg Pharma’s experience from its leading OTC product Kerasal Nail®. Oral terbinafine is the gold standard for treating onychomycosis, but associated with safety issues including drug interactions and liver damage. For many years, developing a topical terbinafine treatment without the safety issues of oral terbinafine has been highly desirable, but unsuccessful due to insufficient delivery of the active substance through the nail. For additional information contact: Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se Kjell Rensfeldt, VP R&D, Phone: +46 707 12 4532, E-mail: kjell.rensfeldt@mobergpharma.se About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Domeboro®, Fiber Choice® and PediaCare®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).
Moberg Pharma announces approvals to start Phase 3 study
Top 10 Most Recent News Articles
AEVEX Faces 48-Hour Deadline for Investor Class Action
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Lundbeck's Board Leadership Transitions into New Era
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
UEG's New Advisory Board: Elevating Patient Voices
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Faith and Resilience in China: The Legacy of the Long March
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue ReadingTop 5 Most Recently Viewed Articles
Huawei eKit Unveils Over 30 Innovative Products to Boost Partners
Huawei eKit Launches New Innovative Solutions In a groundbreaking event, Huawei showcased its commitment to supporting the growth of its partners in the distribution business. The recent forum revealed an impressive array of over 30 new products designed to enhance the competitiveness of Huawei eKit and facilitate the digital transformation journeys of small and medium...
Continue Reading
EDAP TMS Strengthens Board with Joshua H. Levine's Appointment
EDAP TMS Welcomes Joshua H. Levine to Board of Directors EDAP TMS SA (Nasdaq: EDAP), a recognized leader in robotic energy-based therapies, has made a significant addition to its Board of Directors with the appointment of Joshua H. Levine. This strategic move marks a pivotal moment for the company as it continues to strengthen its position within the medical technology...
Continue Reading
Salama's Impressive H1 2025 Growth Highlights Financial Stability
Salama's Remarkable Financial Growth in H1 2025 Salama (DFM: "SALAMA"), one of the leading Takaful providers in the region, has recently announced substantial financial results for the first half of 2025. The company reported a net profit of AED 8.25 million, demonstrating its commitment to operational excellence and sustainability. Profitability Driven by Strong Q2...
Continue Reading
Navigating the Rise of Intraoral Scanners in Modern Dentistry
Understanding the Growth of Intraoral Scanners The global intraoral scanners market is experiencing a remarkable transformation, projecting a leap from US$ 786.5 million in 2024 to a staggering US$ 1,798.8 million by 2033. This growth signals a compound annual growth rate (CAGR) of 9.6% between 2025 and 2033, indicating a significant shift towards digital solutions in...
Continue Reading
Revolutionizing Risk Management: Oscilar's Innovative AI Agents
Revolutionizing Risk Management with AI Oscilar Launches Revolutionary Agentic AI Platform Transforming Risk Decisioning Oscilar, the leading innovator in AI-driven risk management, has announced the launch of its groundbreaking AI Agent platform, reshaping how organizations manage online risk. Built around a network of specialized AI agents, Oscilar's platform addresses...
Continue Reading